← All trials
NCT06470243
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2024
- Primary completion
- Jun 30, 2027
- Completion date
- Apr 30, 2032
- First posted
- Jun 24, 2024
- Last posted
- Nov 1, 2024
- Enrollment
- 528
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SWOG Cancer Research NetworkLead sponsor
- SWOG Cancer Research NetworkOfficial
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.